Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(14)
Filter by content year
(-)
2021
(14)
Filter by form group
Filter by category
All
(14)
(-)
Clinical
(14)
(-)
Science
(14)
Collaborators
(12)
Other
(8)
Filter by category
Search
News
Pfizer-BioNTech COVID-19-Impfstoff löst in vitro neutralisierende Antikörperantwort gegen SARS-CoV-2 mit einer Mutation aus, die mit einer schnellen Übertragung assoziiert wird
News
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
News
BioNTech präsentiert neue klinische Daten aus seinem ersten CAR-T-Programm BNT211 in Late-Breaking-Kurzvortrag auf der 36. SITC-Jahrestagung
News
BioNTech to Present New Clinical Data from First-in-Class CAR-T Program BNT211 in Late-breaking Session at 36th SITC Annual Meeting
News
BioNTech erhält FDA-Fast-Track-Status für FixVac-Kandidaten BNT111 bei fortgeschrittenem Melanom
News
BioNTech Receives FDA Fast Track Designation for its FixVac Candidate BNT111 in Advanced Melanoma
News
Weitere Datenanalyse der Phase-3-Studie bestätigt Sicherheit und hohe Wirksamkeit des Pfizer-BioNTech COVID-19-Impfstoffs bei Jugendlichen im Alter von 12 bis 15 Jahren
News
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
News
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für COMIRNATY® bei Kindern von 5 bis unter 12 Jahren in der Europäischen Union
News
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union
Pagination
Page 1
Next page
››